Source:http://linkedlifedata.com/resource/pubmed/id/10905558
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2000-10-27
|
| pubmed:abstractText |
Stabilized antisense lipid particles (SALP) have been developed for the systemic delivery of oligonucleotides. The impact of intravenous SALP administration was measured with respect to activation of natural killer (NK) and NK1.1+ T (NKT) cells in the livers of immunocompetent mice. Treatment with a SALP containing a highly mitogenic oligonucleotide (INX-6295) generated an increase in NK cytolytic activity and cell number within the liver but did not appear to affect the number of hepatic NKT cells or their cytolytic activity. The same results were observed after intravenous administration of the mitogenic oligonucleotide alone. Interestingly, treatment with a SALP containing a weakly mitogenic oligonucleotide (INX-6300) also activated the liver NK cells, whereas the oligonucleotide alone was unable to elicit these effects. The NK stimulatory activity of a SALP containing INX-6300 required both lipid and oligonucleotide components. These results demonstrate that in addition to modifying the pharmacokinetics and biodistribution of intravenously administered oligonucleotides, SALP possess immunostimulatory activity independent of oligonucleotide mitogenicity, which can serve as an adjuvant to antisense therapies for cancer.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Carriers,
http://linkedlifedata.com/resource/pubmed/chemical/Lipids,
http://linkedlifedata.com/resource/pubmed/chemical/Mitogens,
http://linkedlifedata.com/resource/pubmed/chemical/Oligonucleotides, Antisense
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1087-2906
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
217-24
|
| pubmed:dateRevised |
2003-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:10905558-Adjuvants, Immunologic,
pubmed-meshheading:10905558-Animals,
pubmed-meshheading:10905558-Cell Division,
pubmed-meshheading:10905558-Cell Line,
pubmed-meshheading:10905558-CpG Islands,
pubmed-meshheading:10905558-Drug Carriers,
pubmed-meshheading:10905558-Female,
pubmed-meshheading:10905558-Injections, Intravenous,
pubmed-meshheading:10905558-Killer Cells, Natural,
pubmed-meshheading:10905558-Leukocytes, Mononuclear,
pubmed-meshheading:10905558-Lipids,
pubmed-meshheading:10905558-Liver,
pubmed-meshheading:10905558-Lymphocyte Activation,
pubmed-meshheading:10905558-Lymphocyte Count,
pubmed-meshheading:10905558-Mice,
pubmed-meshheading:10905558-Mice, Inbred C57BL,
pubmed-meshheading:10905558-Mice, Mutant Strains,
pubmed-meshheading:10905558-Mitogens,
pubmed-meshheading:10905558-Oligonucleotides, Antisense
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Intravenous administration of stabilized antisense lipid particles (SALP) leads to activation and expansion of liver natural killer cells.
|
| pubmed:affiliation |
Center for Gene Therapeutics, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
|
| pubmed:publicationType |
Journal Article
|